Although NLS is more a health stock rather than a biotech, its worth mentioning. They preannounced $60 million sales for Q4. With costs down about $3 million per quarter and 40% margins, they should report $.15 to $.20 EPS. Executives just awared themselves a bunch of options at $2.85. I think this sees $4 soon. http://finance.yahoo.com/news/Nautilus-Announces-Strong-bw-2382854812.html?x=0
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.